Search

Renal stem or progenitor cells (RSCs), labeled with CD24 and CD133, play an important role during the repair of renal injury. Bmi-1 is a critical factor in regulating stemness of adult stem cells or progenitor cells. To investigate whether Bmi-1 determines the stemness of RSCs by inhibiting p16 and p53 , and/or maintaining redox balance, RSCs were isolated, cultured and analyzed for stemness characterizations. In RSCs from Bmi-1- deficient (Bmi-1 −/− ) mice and wild type (WT) littermates, self-renewal, stemness, and expressions of molecules for regulating redox balance and cell cycle progression were compared. Self-renewal of RSCs from Bmi-1 and p16 double-knockout (Bmi-1 −/− p16 −/− ), Bmi-1 and p53 double-knockout (Bmi-1 −/− p53 −/− ) and N-acetylcysteine (NAC)-treated Bmi-1 −/− mice were further analyzed for amelioration. Human renal proximal tubular epithelial cells (HK2) were also used for signaling analysis. Our results showed that third-passage RSCs from WT mice had good stemness; Bmi-1 deficiency led to the decreased stemness, and the increased apoptosis for RSCs; NAC treatment or p16/p53 deletion ameliorated the decreased self-renewal of RSCs in Bmi-1 deficiency mice by maintaining redox balance or inhibiting cell cycle arrest respectively; Oxidative stress (OS) could negatively feedback regulate the mRNA expressions of Bmi-1 , p16 and p53. In conclusion, Bmi-1 determined the stemness of RSCs through maintaining redox balance and preventing cell cycle arrest. Thus, Bmi-1 signaling molecules would be novel therapeutic targets for maintaining RSCs and hampering the progression of kidney diseases to prevent renal failure. • Renal stem or progenitor cells (RSCs) own good stemness and multipotency. • Bmi-1 maintains self-renewal and stemness of RSCs by inhibiting ROS, p16 and p53. • Accumulated ROS or p16 or p53 decreases self-renewal and stemness of RSCs. • NAC treatment or p16 or p53 deletion ameliorates the decreased self-renewal of RSCs. • Oxidative stress negatively feedback regulates the expression of Bmi-1 , p16 or p53. [ABSTRACT FROM AUTHOR]

The glucagon-like peptide-1 analog liraglutide has been proved to exert cardioprotective role via activating prosurvival pathways and suppressing inflammation. The activation of NLRP3 inflammasome plays an important role in ischemic injury. The effect of liraglutide on NLRP3 inflammasome-dependent pyroptosis remains unclear. In this study, we established a double stimulation model with TNF-α and hypoxia to mimic ischemic environment and to induce NLRP3 inflammasome activation in H9c2 cardiomyoblasts. Pretreatment with 100 nM liraglutide could efficiently inhibit TNF-α and hypoxia-induced inflammasome activation, as evidenced by the decreased expression of NLRP3, caspase-1 p20 and Gasdermin D N-terminal fragment. Meanwhile, the pyroptosis was also demonstrated to be suppressed, indicated by the increased cell viability and decreased lactate dehydrogenase release in the cells. Mechanistically, liraglutide reversed the level of SIRT1 and the selective SIRT1 inhibitor EX 527 significantly abolished the anti-pyroptosis role of liraglutide. Furthermore, liraglutide diminished the levels of ROS generation and NOX4 expression, which could also be blocked by EX 527. Our results uncovered the anti-pyroptosis role of liraglutide in TNF-α and hypoxia-stimulated H9c2 cells, which was associated with SIRT1/NOX4/ROS pathway. [ABSTRACT FROM AUTHOR]

Breast cancer is the most common cancer among women worldwide. Chemoresistance remains to be a considerable obstacle in breast cancer therapy and it is often involves dysregulation of a variety of microRNAs (miRNAs). miR-485-5p functions as a tumor suppressor in several types of human cancers. However, its role in breast cancer chemosensitivity have not been determined. In the present study, we demonstrated that overexpression of miR-485-5p suppresses breast cancer progression and enhances chemosensitivity both in vitro and in vivo . Further study demonstrated that miR-485-5p directly targeted the 3′-untranslated region of survivin and overexpression of survivin overcomes the miR-485-5p induced effects on breast cancer. In conclusion, our study identified that miR-485-5p suppresses cancer progression and enhances the chemosensitivity by targeting survivin. Targeting survivin by miR-485-5p may provide a potential approach to reverse chemosensitivity in breast cancer cells. [ABSTRACT FROM AUTHOR]

Highlights: [•] FOXD3 is down-regulated in breast cancer tissues. [•] FOXD3 inhibits breast cancer cell proliferation and invasion. [•] FoxD3 deficiency induces epithelial–mesenchymal transition. [ABSTRACT FROM AUTHOR]